TRINETRA › Sectors › Healthcare
Narayana Hrudayalaya Ltd. (NH) — share price, P/E and fundamentals
Narayana Hrudayalaya Ltd. (NSE: NH) closed at ₹1,718.70 on 30 Oct 2026, -2.1% over one year, against a 52-week range of ₹1,589.00 – ₹2,093.30.
In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹2,844 cr and net profit of ₹301 cr, a 10.6% net margin; revenue grew 73.0% and profit grew 15.7% year on year.
On four consecutive filed quarters its trailing P/E is 40.9; since 26 May 2025 its own P/E has ranged from 40.4 to 58.2 (median 46.9), and today's reading is higher than 0% of those 354 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 24.1%, ROCE 15.7%, debt-to-equity 0.99, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 25% of 63 sector peers; PBT margin higher than 21% of 63 sector peers; ROE higher than 84% of 63 sector peers.
Key figures
| Last close | ₹1,718.70 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -8.5% / -2.8% / -2.1% |
| 52-week low – high | ₹1,589.00 – ₹2,093.30 |
| Market capitalisation | ₹35,124 cr |
| Trailing P/E | 40.9 |
| Price / book | 7.02 |
| EV / EBITDA | 19.9 |
| Earnings yield | 2.5% |
| TTM EPS | ₹42.02 |
| TTM net profit | ₹859 cr |
| Quarter revenue | ₹2,844 cr |
| Quarter net profit | ₹301 cr |
| Net margin | 10.6% |
| Revenue growth (YoY) | +73.0% |
| Profit growth (YoY) | +15.7% |
| Return on equity | 24.1% |
| ROCE | 15.7% |
| Debt / equity | 0.99 |
| Current ratio | 2.15 |
| Free cash flow | ₹594 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹30.3 cr |
Against Healthcare peers
| Metric | NH | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.58 | 12.89 | 25 |
| PBT margin | 12.07 | 17.68 | 21 |
| ROE | 24.07 | 13.86 | 84 |
| ROCE | 15.66 | 17.26 | 40 |
| Debt / equity | 0.99 | 0.11 | 98 |
| FCF margin | 10.74 | -0.87 | 60 |
| Cash conversion | 1.91 | 1.25 | 80 |
| Trailing P/E | 40.90 | 43.26 | 44 |
Questions
What is the P/E ratio of Narayana Hrudayalaya Ltd.?
Narayana Hrudayalaya Ltd.'s trailing P/E is 40.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 26 May 2025 its P/E has ranged 40.4–58.2.
What were Narayana Hrudayalaya Ltd.'s latest quarterly results?
For the quarter ended 30 Sept 2026, Narayana Hrudayalaya Ltd. reported revenue of ₹2,844 cr and net profit of ₹301 cr (consolidated), filed with the exchange on 30 Oct 2026.
What is Narayana Hrudayalaya Ltd.'s ROE?
Return on equity is 24.1% based on the balance sheet dated 30 Sept 2026.
Does Narayana Hrudayalaya Ltd. have debt?
Debt-to-equity is 0.99 on the balance sheet dated 30 Sept 2026.
What is NH's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, NH traded between ₹1,589.00 and ₹2,093.30.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.